Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Angle, Arrow Exploration, Bushveld, Block, Cizzle,

Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Angle, Arrow Exploration, Bushveld, Block, Cizzle,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Arrow, Angle, CentralNic, Clontarf, Emmerson, ECSC,
Open Orphan (ORPH), a specialist contract research organisation, said that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated
Lift Global Ventures (LFT), the financial media and technology investor, unveiled its listing date on Aquis as April 29. The company has raised £1.7m in its IPO, led by stock
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Amigo, Angle, Avacta, Audioboom, Cadogan, Deltic,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Angle, Audioboom, Capital Metals, Cellular, European
Canadian Overseas Petroleum (COPL), an international oil and gas exploration, production and development company, announced financial results for the fourth quarter of 2021 and for the year ending December 31,
It is clear that most stock suspensions on the London market are unnecessary and usually the result of an overzealous regulator enjoying providing private investors with a deep hole in
Zak Mir takes a charting look at some of the most followed small caps. Today’s selection includes AfriTin, Arrow Exploration, Alkemy, Angus, Aminex, Angle, Blue Star, Cordel, Galantas, Hurricane, Minoan,
Open Orphan (ORPH), a rapidly growing specialist contract research organisation announces is growing yet further. hVIVO, a subsidiary of Open Orphan, has signed a £5m respiratory syncytial virus human challenge
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER